February 25, 2019 07:47 AM EST
R&D

As­traZeneca's clot-fight­er Bril­in­ta shows promise in di­a­bet­ics with heart dis­ease in big study

Natalie Grover

Reporter

As Pas­cal So­ri­ot pol­ish­es the rough edges of his R&D shop with­in As­traZeneca, the British drug­mak­er re­port­ed some en­cour­ag­ing news that could help it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

A service from the Financial Times